Kerri Fitzgerald

Kerri Fitzgerald

Kerri Fitzgerald

Kerri Fitzgerald is a medical writer and editor with over 10 years of experience writing mostly in the hematology/oncology space. She can be reached at kfitzgerald@mashupmd.com.

Articles by Kerri Fitzgerald

Kerri FitzgeraldConferences | June 14, 2022
The results were presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
Read More
Kerri FitzgeraldConferences | June 14, 2022
Just 38% of patients with breast cancer receive at least 1 palliative care consult following metastatic disease diagnosis.
Kerri FitzgeraldConferences | June 14, 2022
All stakeholders have a role to play in increasing representation in this patient population.
Kerri FitzgeraldConferences | June 14, 2022
A study identified self-reported gaps from healthcare providers associated with providing treatment-related support.
Kerri FitzgeraldMPN | April 7, 2021
A kidney biopsy may help identify new molecular targets to prevent the development of kidney fibrosis.
Kerri FitzgeraldMyelofibrosis | April 7, 2021
Review outcomes in patients with myelofibrosis who choose to undergo HCT versus non-transplant therapies.
Kerri FitzgeraldMPN | April 7, 2021
The retrospective study included 300 adults with MPN who were seen between January 1992 and January 2019.
Kerri FitzgeraldMPN | April 7, 2021
The study was published in the journal Acta Haematologica.
Kerri FitzgeraldMyelofibrosis | March 9, 2021
A study presented as part of the ASH 2020 Annual Meeting found that use of fedratinib for 24 or more weeks was well-tolerated ...
Kerri FitzgeraldMyelofibrosis | March 9, 2021
Interferon-alpha (rIFN?) is the only disease-modifying treatment option for polycythemia vera (PV). A study published in ...
Kerri FitzgeraldMyelofibrosis | March 9, 2021
The Janus kinase (JAK) inhibitor ruxolitinib was U.S. Food and Drug Administration-approved for patients with high-risk ...
Kerri FitzgeraldMyelofibrosis | March 3, 2021
A study presented as part of the ASH 2020 Annual Meeting found that imetelstat improved overall survival (OS) in patients ...
Kerri FitzgeraldMyelofibrosis | March 3, 2021
A study presented at the 2021 Transplantation and Cellular Therapy Meetings found that peri-transplant ruxolitinib was safe ...
Kerri FitzgeraldMPN | February 24, 2021
A study published in Blood Advances observed a high risk of recurrent thrombotic events in patients with myeloproliferative ...
Kerri FitzgeraldHematology & Blood Cancer | February 24, 2021
A study published in Hematological Oncology found that overweight/obese patients with polycythemia vera (PV) do not have an ...
Kerri FitzgeraldMPN | February 24, 2021
A study published in Hematology/Oncology and Stem Cell Therapy did not observe a significant difference in the rate of ...
Kerri FitzgeraldMyelofibrosis | February 11, 2021
A study published in the American Journal of Blood Research observed a link between serum ferritin level and fibrosis in ...
Kerri FitzgeraldMPN | February 11, 2021
Pulmonary hypertension is common in patients with Philadelphia?chromosome negative myeloproliferative neoplasms (MPN). ...
Kerri FitzgeraldMyelofibrosis | February 11, 2021
The effect of bone marrow (BM) blasts on the outcome of patients with myelofibrosis (MF) is poorly understood, except for in ...
Kerri FitzgeraldHematology & Blood Cancer | February 8, 2021
The CALR mutation has prognostic value for the stratification of thrombotic risk in patients with essential thrombocytopenia ...